Glenmark Stock Jumps Cancer Drug Deal

  Published 9 months ago

Glenmark’s stock rises as Swiss unit secures Hengrui’s trastuzumab rezetecan licence, boosting outlook for investors.

  • Deal includes $18 million upfront and up to $1.09 billion in milestone payments for Hengrui drug rights
  • Nomura predicts the drug will drive Glenmark’s $350‑400 million innovation revenue target over the next five years alone
  • Analysts rate Glenmark “buy”; median price target 2,400 rupees, stock up 27% YTD 2025 so far

You might like these

Lupin Wins FDA Nod for Risperidone

RateGain Powers Green Motion Growth

Torrent Buys JB Pharma Stake, Plans Merger with KKR Exit

Trump Tariff Sparks India-U.S. Trade Row

Infosys & Telstra Announce Partnership

Indus Towers Q1 Profit Falls 10%

RBI Notes India’s Economic Resilience

News that matters the most ⚡